Knowledge is power when living with ovarian cancer.
Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.Already a subscriber? Sign in here
FATE-NK100 Shows Signs of Tumor Reduction in First Ovarian Cancer Patients in Phase 1 Trial
FATE-NK100, a natural killer cell immunotherapy, induced stable disease in one of the first two heavily treated ovarian cancer patients in a Phase 1 trial. No dose-limiting toxicities have been reported so far, Fate Therapeutics announced. The findings were recently revealed during the oral presentation, “Novel strategies to activate Adaptive NK cells and Make them antigen specific,” at